Advertisement

Topics

Bristol-Myers Squibb’s Opdivo gets FDA nod for additional indication in colon cancer

02:29 EDT 2 Aug 2017 | Pharmaceutical Business Review

Bristol-Myers Squibb’s Opdivo (nivolumab) injection has secured approval from the US Food and Drug Administration to treat a subtype of metastatic colorectal cancer (mCRC).

Original Article: Bristol-Myers Squibb’s Opdivo gets FDA nod for additional indication in colon cancer

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb’s Opdivo gets FDA nod for additional indication in colon cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...